Latest project updates
Oncode Institute aims to outsmart cancer and impact lives. To achieve this, Oncode focuses on three pillars: excellent research, intensive collaboration and powerful valorization. The research strategy is focused on understanding the basic mechanisms of cancer to realize the ultimate goal: safer and more effective medical solutions as well as personalized precision diagnostics. Oncode brings together excellent cancer researchers in The Netherlands: 61 research groups from 12 different Dutch research institutes collaborate on 6 interdisciplinary research themes. To speed up the translation of scientific discoveries into clinical applications, Oncode has a dedicated team of specialists to support scientists in the valorization process.
12 partner institutions
61 Principal Investigators
€ 120 million
funding for 5 years
About Oncode Institute
Over the past decades, the scientific and medical community has made tremendous progress in understanding and treating cancer. However, the disease still has a large burden on society as cancer has become the primary cause of death in The Netherlands. In an effort to address this unmet clinical need, Dutch cancer researchers have joined forces within Oncode Institute. To come up with new avenues for treatment and diagnosis, Oncode focuses on better understanding the fundamental mechanisms of cancer biology. With the ultimate goal to improve long-term survival and the quality of life of patients.Oncode serves as a platform for excellent cancer researchers in The Netherlands to collaborate, share knowledge, expertise and technology. As a virtual Institute it stimulates scientific freedom and offers dedicated support to optimize the translation of fundamental insights into clinical applications. Outsmarting cancer, impacting lives. Visit the Oncode website for more information about the project.
Over 800+ Oncode researchers working under a single strategy that focuses on six different research themes:
- Development of novel technologies
- Understanding the critical drivers of tumour growth and the causes of resistance
- Analysis of network perturbations in tumours and tumour-host interactions
- Causes and consequences of genetic instability
- Identification of critical drug combinations and biomarkers for personalized cancer treatments
- Mobilising immune defence
Oncode invests heavily in the transfer of results from fundamental research into clinical applications. A team of dedicated specialists will help Oncode researchers with valorization of their findings. Furthermore, Oncode offers tailored training programs for affiliated researchers and actively invests in diversity through its Young Female Investigator program.
Accelerating innovation by partnership management
Based on its broad experience with partnership management and communication, Lygature has become a partner of Oncode. Lygature supports Oncode Institute with the following services:
- Program management
- Communication & external affairs
- Finance & IT-infrastructure
- Patient engagement
Lygature together with
Project updates
-
Minister De Jonge visits COVID-19 test robot co-invented by Oncode Investigators Tanenbaum and De Laat
Last Wednesday, January 27th, Dutch Minister of health Hugo de Jonge visited the medical microbiology laboratories at PAMM to witness the newly installed STRIP-1 test robot which was installed end of the year. This test robot is capable of processing 20.000 COVID-19 qPCR-tests per 24 hours, making it unique in the world. The Dutch government sees an innovative solution in the test robot, also beyond the COVID-19 pandemic, and has planned to eventually install 5 of these systems across the country. “The STRIP can be an important additional link in large-scale testing, which is necessary in a pandemic”, says Minister De Jonge. “It is wonderful that companies and institutes in The Netherlands have managed to do this and the government has been happy to cooperate.”
-
Oncode Investigator Ton Schumacher wins the prestigious Jeantet-Collen Prize for Translational Medicine
The first month of 2021 is not even gone, and we already have some great news. Oncode Investigator Ton Schumacher (NKI) won the renowned Jeantet-Collen Prize for Translational Medicine. This award comes in recognition of his work developing technologies to study the role of the immune system in cancer progression, and for the improvement of cancer diagnosis and treatment. He will share the prize with french scientist Jerome Galon from the Institut National de la Santé et de la Recherche Médicale (INSERM) in Paris.
-
The December edition of Oncode’s digital magazine is here
This issue brings some good news (no spoiler alert, you must read our Editorial), and we hope will also tap into your interests, curiosity and need of reflection.
In our Dialogue section Leila Akkari and Jeanine Roodhart look back at the past months, reflecting on their experiences and the challenges they faced. Oncode Investigator Jarno Drost didn’t always dream of becoming a researcher - after the Dialogue, read further for a chance to get to know him a bit better.
This issue we would also like to make an introduction: Alain Kummer, our new managing director as of last September talks about his new role and about his ambitions in the magazine’s new column section.
Finally, take a deep dive into the work of Oncode Investigator Sylvie Noordermeer, who imitates cancer cells in the lab by inflicting DNA damage, finding new targets for more effective treatments.
All this and much more is just a single click away. Feel free to share our stories and let us know what you think: we like to hear from you!Click here to open the magazine
You can subscribe to our magazine here.